Reappearance and treatment of penicillin-susceptible Staphylococcus aureus in a tertiary medical centre

The Journal of Antimicrobial Chemotherapy
Matthew R ChabotJulius Larioza

Abstract

The purpose of this study was to describe trends in the prevalence and treatment patterns of penicillin-susceptible Staphylococcus aureus (SA) infections. This was a cross-sectional study of MSSA isolates from blood cultures at a tertiary-care centre between 1 January 2003 and 31 December 2012. All blood cultures positive for MSSA drawn during the study period were used to calculate the prevalence of penicillin-susceptible SA. Repeat cultures were excluded if they were isolated within 6 weeks of the index culture. The analysis was then restricted to inpatient blood cultures to assess treatment patterns. Antibiotics administered 48-96 h after the culture were analysed. A total of 446 blood cultures positive for MSSA were included in the analysis. There was a distinct trend showing an increase in the percentage of penicillin-susceptible SA over 10 years from 13.2% (95% CI 4.1%-22.3%) in 2003 to 32.4% (95% CI 17.3%-47.5%) in 2012 (P trend <0.001). During the study period, penicillin use for penicillin-susceptible SA bacteraemia increased from 0.0% in 2003-04 to 50.0% in 2011-12 (P trend = 0.007). Over a decade, there was an ∼3-fold increase in penicillin susceptibility among MSSA blood cultures at a large tertiary-care facility. A...Continue Reading

References

Mar 1, 1997·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·A J LeachJ D Mathews
Aug 26, 1998·The New England Journal of Medicine·F D Lowy
Apr 11, 2001·Emerging Infectious Diseases·H F Chambers
Aug 9, 2013·The Journal of Antimicrobial Chemotherapy·John K Crane
Dec 11, 2013·The Journal of Antimicrobial Chemotherapy·Claudia Slimings, Thomas V Riley
Nov 27, 2014·Euro Surveillance : Bulletin Européen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin·K Weist, L Diaz Högberg

❮ Previous
Next ❯

Citations

Mar 1, 2016·The American Journal of Medicine·Matthew P ChengTodd C Lee
Nov 3, 2017·Journal of Clinical Microbiology·Sanjat KanjilalYonatan H Grad
Jan 15, 2016·Journal of Clinical Microbiology·S S RichterD J Diekema
Feb 12, 2021·Clinical Microbiology Reviews·Soyoun Park, Jennifer Ronholm

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

CRISPR & Staphylococcus

CRISPR-Cas system enables the editing of genes to create or correct mutations. Staphylococci are associated with life-threatening infections in hospitals, as well as the community. Here is the latest research on how CRISPR-Cas system can be used for treatment of Staphylococcal infections.